Digest Network Come funziona
Network
/
Società
bi
Non verificato

bioAffinity Technologies, Inc.

Di cosa scriviamo

Attrezzature medico-sanitarieBiotecnologiaOncologiaSaluteScienza

106 comunicati stampa

Guarda tutti i comunicati
06/11/2026
Mercato azionario
Scienza
Sanità
Medicina nucleare
Farmaceutica
Oncologia
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Igiene alimentare
Salute
bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization
Fonte
bioAffinity Technologies, Inc.
Emittente
Business Wire
1.00
0
29/10/2026
Oncologia
Salute
Scienza
Biotecnologia
Eventi
bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month
Fonte
bioAffinity Technologies, Inc.
Emittente
Business Wire
1.00
0
15/10/2026
Biotecnologia
Salute
Oncologia
Eventi
Industria
bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026
Fonte
bioAffinity Technologies, Inc.
Emittente
Business Wire
1.00
0
13/10/2026
Scienza
Sanità
Medicina nucleare
Farmaceutica
Oncologia
Attrezzature medico-sanitarie
Biotecnologia
Medicina - Varie
Igiene alimentare
Salute
Eventi
bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
Fonte
bioAffinity Technologies, Inc.
Emittente
Business Wire
1.00
0
09/10/2026
Finanza
Oncologia
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Fonte
bioAffinity Technologies, Inc.
Emittente
Business Wire
1.00
0
08/10/2026
Finanza
Oncologia
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Fonte
bioAffinity Technologies, Inc.
Emittente
Business Wire
1.00
0
08/10/2026
Industria
Scienza
Attrezzature medico-sanitarie
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Salute
Oncologia
bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
Fonte
bioAffinity Technologies, Inc.
Emittente
Business Wire
1.00
0
06/10/2026
Pubblico Esercizio/Vendita al dettaglio
Biotecnologia
Farmaceutica
Salute
Oncologia
bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
Fonte
bioAffinity Technologies, Inc.
Emittente
Business Wire
1.00
0
30/09/2026
Eventi
Industria
Scienza
Farmaceutica
Oncologia
Attrezzature medico-sanitarie
Tecnica
Difesa / Forze Armate
Medicina - Varie
Biotecnologia
Salute
bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
Fonte
bioAffinity Technologies, Inc.
Emittente
Business Wire
1.00
0
22/09/2026
Eventi
Industria
Tecnica
Medicina nucleare
Farmaceutica
Oncologia
Attrezzature medico-sanitarie
Difesa / Forze Armate
Medicina - Varie
Scienza
Biotecnologia
Software
Salute
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
Fonte
bioAffinity Technologies, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0